Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05685160
Other study ID # H-20067346
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date June 14, 2021
Est. completion date March 2024

Study information

Verified date January 2023
Source Rigshospitalet, Denmark
Contact Sif B Larsen, MD
Phone +45 21457551
Email binderlarsen@gmail.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The aim of this study is to investigate the incidence of intermetatarsal bursitis and Morton's neuroma in patients with metatarsalgia (i.e. pain in the forefoot) and control subjects by diagnostic imaging with ultrasound and MRI.


Description:

In a group of patients with intermetatarsal pain found by an orthopedic surgeon, the investigators want to assess the incidences of intermetatarsal bursitis and Morton's neuroma, using diagnostic imaging; ultrasound and MRI. The hypothesis is, that intermetatarsal bursitis is an overlooked diagnosis in patients with metatarsalgia. As a result of sparse literature and lack of knowledge about this condition with symptoms mimicking Morton's neuroma, a part of patients diagnosed with Morton's neuroma, suffers from intermetatarsal bursitis instead. Additionally, the investigators want to evaluate the clinical sign opening toes. Based on clinical photos of the feet, the investigators want to document the presence of opening toes and investigate if there is a correlation with either intermetatarsal bursitis and/or Morton's neuroma.


Recruitment information / eligibility

Status Recruiting
Enrollment 75
Est. completion date March 2024
Est. primary completion date January 2024
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age > 18 years - Pain in an intermetatarsal space (patient group) Exclusion Criteria: - Age <18 years - Open wounds or ongoing infection in the forefoot at the time of examination - Persons with contraindications to participate in MRI scan - Persons with a history of significant trauma in the forefoot, e.g. any fracture or previous surgeries in the forefoot - Persons who have previously received treatment for Morton's neuroma in the same foot, e.g. injection (within 6 months) or operation (anytime) - Persons with severely impaired renal function (GFR <30 ml/min) - Persons with a systemic inflammatory condition like rheumatoid arthritis, due to clinically silent intermetatarsal bursitis in this group (control group)

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
MRI with contrast
MRI of the forefoot with contrast (Gadovist)
Ultrasound
Ultrasound imaging of the forefoot

Locations

Country Name City State
Denmark Department of Radiology Copenhagen

Sponsors (5)

Lead Sponsor Collaborator
Rigshospitalet, Denmark Bispebjerg Hospital, Gentofte Hospital, Hvidovre University Hospital, The Danish Rheumatism Association

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Primary Incidence of intermetatarsal bursitis on MRI High intensity on T2 weighted images, low signal on T1. Thin peripheral enhancement on T1 contrast enhanced pictures. 8 weeks
Primary Incidence of intermetatarsal bursitis on US Hypoechoic mass between metatarsal heads closest to dorsal surface of foot. Compressible. Activity on power/color doppler. 8 weeks
Primary Incidence of Morton's neuroma on MRI Low to Intermediate signal in T1 and T2. Contrast enhancement of the nodular focus. 8 weeks
Primary Incidence of Morton's neuroma on US Hypoechoic mass between metatarsal heads closest to plantar surface of foot. Non-compressible. The interdigital nerve can be seen entering the mass. Close relation to the interdigital artery. 8 weeks
Primary Incidence of other pathology on MRI Other pathology than intermetatarsal bursitis or Morton's neuroma. 8 weeks
Primary Incidence of other pathology on US Other pathology than intermetatarsal bursitis or Morton's neuroma. 8 weeks
Primary Incidence of normal findings on MRI When no findings is observed. 8 weeks
Primary Incidence of normal findings on US When no findings is observed. 8 weeks
Secondary Opening toes Presence of opening toes/V-sign/spreading toes. 8 weeks
See also
  Status Clinical Trial Phase
Completed NCT05707572 - Morton's Neuroma: Manipulation Versus Steroid Injection N/A
Active, not recruiting NCT05550831 - Radiofrequency Before to Surgical Removal of a Recalcitrant Morton´s Neuroma N/A
Completed NCT03504462 - Feasibility of Specific Anesthesia of the Forefoot Preserving the Sensitivity of the Heel for Foot Surgery N/A
Recruiting NCT05411224 - Investigation of the Effect of Custom Made Insoles on Foot Pressure Distribution and Gait Parameters in Patients With Morton's Neuroma N/A
Completed NCT03511677 - Insole on Morton's Neuroma N/A
Recruiting NCT05501262 - Comparative Effectiveness of Cryoablation Versus Steroid and Lidocaine Alone for Treatment of Morton's Neuroma N/A
Completed NCT05012488 - Comparison of the Effects of Morton's Neuroma on Foot Pressure Distribution and Gait Parameters in Pes Planus and Pes Cavus Patients
Recruiting NCT03046108 - Blind and Ultrasound Guided Injection in Morton Neuroma Phase 4
Withdrawn NCT00284414 - Is Ultrasonography Comparable to MRI for the Detection of Morton Neuroma of the Foot? N/A